8月4日，泰林生物今日收盘24.42元，上涨1.50%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到276.46倍，总市值29.60亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，泰林生物排 名第117位。 资金流向方面，8月4日，泰林生物主力资金净流出170.99万元，近5日总体呈流出状态，5日共流出 1614.61万元。 浙江泰林生物技术股份有限公司的主营业务是生命科学领域微生物检测与污染控制、创新药物研发生 产、过程分析和阻遏防护等产品的研发、生产和推广应用，为生物医药、医疗保健、食品饮料、环境保 护等行业提供具有高质量的产品和解决方案。公司的主要产品是集菌仪、集菌培养器、微生物检验仪、 微孔滤膜、酶底物法大肠菌群检测系统、酶底物智能培养计数系统、全自动两虫检测系统、生物指示 剂、生物指示剂抗力仪、质控菌株、隔离器、无菌传递舱、阻遏隔离器、多功能细胞处理工作站、蜂巢 培养系统（转运车+蜂巢培养箱）、无菌分装工作站、汽化过氧化氢发生器、过氧化氢雾化消毒机、全 自动菌落计数工作站、全自动无菌检查培养系统、细菌侵入测试仪、TOC分析仪、固体燃烧 ...

Group 1 - The core viewpoint of the news highlights a significant rise in virus prevention stocks, particularly in response to the reported cases of Chikungunya fever in Foshan, Guangdong Province [1][2][3] - Notable stock performances include Zhifei Biological, which increased by 16.86%, and Watson Bio, which rose by 13.39%, among others [2] - The total market capitalization of Zhifei Biological is reported at 57.7 billion, while Watson Bio stands at 21 billion [2] Group 2 - As of July 22, Foshan has reported a total of 3,195 confirmed cases of Chikungunya fever, primarily concentrated in the Shunde District [2] - The World Health Organization has issued a warning regarding mosquito-borne diseases, urging countries to prepare for potential outbreaks [3]

Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. specializes in microbial testing and pollution control, innovative drug research and production, process analysis, and protective measures in the life sciences sector [2] - The company provides high-quality products and solutions for industries such as biomedicine, healthcare, food and beverage, and environmental protection [2] Financial Performance - For Q1 2025, the company reported revenue of 66.94 million yuan, a year-on-year decrease of 16.33% [2] - The net profit for the same period was 3.53 million yuan, down 39.93% year-on-year, with a sales gross margin of 49.27% [2] Market Position - As of July 22, the company's stock closed at 22.8 yuan, with a rolling price-to-earnings (PE) ratio of 258.12, marking a new low in 163 days [1] - The average PE ratio in the medical device industry is 53.47, with a median of 37.00, placing Tailin Biological at the 117th position in the industry ranking [1][3] Shareholding Structure - As of Q1 2025, there is one institutional holder of Tailin Biological, which is a fund holding 511,200 shares valued at 1.1 million yuan [1]

Group 1 - Yaxin Security plans to reduce its shareholding by up to 3%, totaling no more than 12 million shares, from August 8, 2025, to November 7, 2025 [1] - Shangwei Co. intends to issue up to 180 million shares to its controlling shareholder, raising no more than 1.144 billion yuan for digital upgrades and working capital [1][2] - Anker Innovations is exploring the possibility of overseas share issuance to enhance its global strategy and brand image, with no specific plan confirmed yet [3] Group 2 - AVIC Xi'an Aircraft Industry Group's chairman resigned due to work changes, effective immediately upon submission of the resignation [4] - Tianci Materials signed a procurement cooperation agreement to supply at least 550,000 tons of electrolyte products to Chuangneng New Energy from 2025 to 2030, enhancing market share and profitability [5][6] - Guangshentang's innovative drug GST-HG131 has been included in the list of breakthrough therapies, but this does not guarantee market approval or immediate financial impact [7][8] Group 3 - Chaozhuo Aerospace plans to reduce its shareholding by up to 3%, totaling no more than 896,000 shares, from August 7, 2025, to November 6, 2025 [9] - Taiji Group intends to repurchase shares worth between 80 million and 120 million yuan, with a maximum price of 28.03 yuan per share, to be used for cancellation [11][12] - Xibu Materials plans to invest 125 million yuan in a private placement by its subsidiary to raise 147 million yuan for working capital and loan repayment [13] Group 4 - Shantui Co. plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [14] - *ST Huawang intends to acquire 55.5% of Niwei Power for 666 million yuan, entering the new energy hybrid vehicle sector [15] - Tailin Bio's controlling shareholder plans to reduce its shareholding by up to 1.5%, totaling no more than 1.8195 million shares, for personal funding needs [17] Group 5 - Huicheng Vacuum plans to reduce its shareholding by up to 3%, totaling no more than 3 million shares, from August 7, 2025, to November 6, 2025 [18][19] - Kesi Co.'s actual controller plans to reduce its shareholding by up to 3%, totaling no more than 14.27 million shares, for personal funding needs [20][21] - Zhongchong Co.'s controlling shareholder plans to reduce its shareholding by up to 1.5%, totaling no more than 4.56 million shares, for funding needs [22][23] Group 6 - Shanhigh Environmental plans to raise no more than 718 million yuan through a private placement to supplement working capital and repay bank loans [24][25] - Zhongrong Electric plans to invest 114 million yuan in the construction of the Sinok New Energy Technology Park, expected to be completed by the end of 2027 [26] - Kaisen New Materials' shareholder plans to transfer 4.75% of its shares, totaling 20 million shares, for personal funding needs [27] Group 7 - Xinxin Standard's controlling shareholder plans to reduce its shareholding by up to 3%, totaling no more than 6.7792 million shares, for personal funding needs [28] - Chuhuan Technology plans to invest 9.99 million yuan in a partnership focused on high-end manufacturing, including semiconductors and new materials [29] - Shankai Intelligent's stock will resume trading after a share transfer agreement with Changjiang Aerospace, which will become the controlling shareholder [30]

智通财经7月16日电，泰林生物(300813.SZ)公告称，持股5%以上股东暨控股股东、实际控制人的一致行 动人高得投资计划通过集中竞价、大宗交易或两者相结合等方式，于本减持计划公告之日起15个交易日 后的3个月内减持公司股份不超过1,819,517股，占公司总股本的1.50%。减持价格将根据减持时的股票 市场价格确定。 泰林生物：股东高得投资拟减持不超过1.5%公司股份 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-057 浙江泰林生物技术股份有限公司 关于持股 5%以上股东暨控股股东、实际控制人的一致行动人 减持股份预披露公告 公司持股 5%以上股东暨控股股东、实际控制人的一致行动人青岛高得投资 合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 持有本公司7,278,070股（占公司总股本6.01%）的持股5%以上股东暨控股股 东、实际控制人的一致行动人青岛高得投资合伙企业（有限合伙）（曾用名：宁 波高得股权投资管理合伙企业（有限合伙），以下简称"高得投资"）计划通过 集中竞价、大宗交易或两者相结合等方式于本减持计划公告之日起15个交易日后 的3个月内减持公司股份不超过1,819,517股，占公司总股本的1.50%，其中，通 过证券交易所集中竞价交易方式进行减持的，任意连续90个自然日内减持股份的 总数不超过公司股份总数的1%；通过大宗交易方式进行减持的，任意连续90个自 然日内减持股份的总数不 ...

Core Viewpoint - The announcement details the transfer of 12.1 million shares (9.9836% of total share capital) from the controlling shareholder and actual controller Ye Daling to Ni Weiju, which has been completed as of July 15, 2025. The transfer does not involve any secondary market reduction and will not change the company's controlling shareholder or actual controller [1]. Summary by Categories - **Share Transfer Details** - Ye Daling transferred 12.1 million shares to Ni Weiju, representing 9.9836% of the company's total share capital [1]. - The transfer was completed on July 15, 2025, with the registration of the transfer [1]. - **Commitment from New Shareholder** - Ni Weiju has committed not to reduce the shares acquired through this transfer in any way for 12 months following the completion of the transfer [1]. - **Impact on Company Control** - The transfer does not involve any secondary market reduction and will not lead to a change in the company's controlling shareholder or actual controller [1].

Overview - The announcement details the completion of a share transfer agreement between the controlling shareholders of Zhejiang Tailin Biological Technology Co., Ltd, specifically between Mr. Ye Dalin and Ms. Ni Weijun, involving 12,100,000 shares, which represents 9.9836% of the company's total share capital [1][9]. Share Transfer Details - The share transfer was executed through an internal agreement and does not involve any reduction in the secondary market, ensuring that the total shareholding of Mr. Ye Dalin and Ms. Ni Weijun remains unchanged [1][9]. - The share transfer agreement was signed on May 30, 2025, and the transfer was completed on July 15, 2025 [1][7]. Financial Terms - The transfer price was set at RMB 15.216 per share, totaling RMB 184,113,600 (approximately 184.11 million) [3][5]. - Payment for the shares is to be completed within one year following the transfer [3][5]. Shareholder Commitments - Ms. Ni Weijun has committed not to reduce her holdings from this transfer for a period of 12 months following the completion of the transfer [2][9]. - Both parties have confirmed that the transfer does not affect the company's financial status or the interests of minority investors [1][9]. Regulatory Compliance - The transfer has been confirmed as compliant with relevant regulations, and necessary documentation has been submitted to the Shenzhen Stock Exchange [4][8].

证券代码：300813 证券简称：泰林生物 公告编号：2025-056 关于控股股东、实际控制人之间内部协议转让股份完成过户 登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 浙江泰林生物技术股份有限公司 1．浙江泰林生物技术股份有限公司（以下简称"公司"）收到公司控股股 东、实际控制人叶大林先生、倪卫菊女士提供的中国证券登记结算有限责任公司 出具的《证券过户登记确认书》，倪卫菊女士以协议转让的方式受让叶大林先生 所持有的公司 12,100,000 股（占公司总股本的 9.9836%），已于 2025 年 7 月 15 日办理完成过户登记（以下简称"本次协议转让"）。 2．倪卫菊女士承诺在过户完成之日起 12 个月内不会以任何方式主动减持本 次转让中取得的股份。 3．本次协议转让事项属于公司控股股东、实际控制人叶大林先生、倪卫菊 女士之间的内部转让，不涉及二级市场减持，不会导致叶大林先生、倪卫菊女士 及其一致行动人合计持股数量和比例发生变化。 4．本次股份转让不触及要约收购，亦不会导致公司控股股东及实际控制人 发生变化，不会对公司财务状况 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-055 浙江泰林生物技术股份有限公司 关于全资子公司变更注册资本并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）于2025年6月13日召 开第四届董事会第八次会议，审议通过了《关于使用募集资金向全资子公司增资 的议案》。本次增资完成后，浙江泰林新材料有限公司（以下简称"泰林新材料"） 的注册资本由1,000万元变更为10,000万元，仍为公司全资子公司。具体内容详 见披露于巨潮资讯网的《关于使用募集资金向全资子公司增资的公告》（公告编 号：2025-045）。 近日泰林新材料已完成工商变更登记手续并取得了杭州市富阳区市场监督 管理局核发的《营业执照》，相关变更情况如下： 除上述注册资本变更外，其他工商登记信息不变。 二、本次变更后的《营业执照》相关登记信息 1．公司名称：浙江泰林新材料有限公司 5．法定代表人：沈志林 6．注册资本：壹亿元整 7．住所：浙江省杭州市富阳区春江街道富春湾大道 2723 号 17 幢 578 号 ...